The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1a dose-escalation study of PY314, a TREM2 (Triggering Receptor Expressed on Macrophages 2) targeting monoclonal antibody.
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Theraeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Erika P. Hamilton
Consulting or Advisory Role - Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Akeso Biopharma (Inst); Amgen (Inst); Aravive (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); AtlasMedx (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); Ellipses Pharma (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Incyte (Inst); InventisBio (Inst); Jacobio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Myriad Genetics (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); ORIC Pharmaceuticals (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Radius Health (Inst); Regeneron (Inst); Repertoire Immune Medicines (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Treadwell Therapeutics (Inst); Verastem (Inst); Vincerx Pharma (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Ira Seth Winer
Research Funding - Oncoceutics
 
Winston Tan
Honoraria - Medscape; Onclive
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst); BeiGene (Inst); Merck; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Merck (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Erin Lynn Schenk
Honoraria - Roche/Genentech; Takeda
Consulting or Advisory Role - Abbvie; Bionest partners; ExpertConnect; FCB Health; Guidepoint Global; Regeneron; Regeneron; the KOL Connection Ltd
Speakers' Bureau - Physicans' Education Resource
Other Relationship - Elsevier
 
Mohamad B. Sonbol
No Relationships to Disclose
 
Nadine Jahchan
Employment - Pionyr
Leadership - Pionyr
Stock and Other Ownership Interests - Pionyr
Research Funding - Gilead Sciences
 
Kristen Pierce
Employment - Pionyr
Leadership - Pionyr
Stock and Other Ownership Interests - Pionyr
Research Funding - Gilead Sciences
 
Yunfeng Li
Employment - Pionyr
Leadership - Pionyr
Stock and Other Ownership Interests - Pionyr
 
Len Reyno
Employment - Pionyr
Leadership - Pionyr
Stock and Other Ownership Interests - Pionyr
 
Marc Chamberlain
Employment - Pionyr
Leadership - Pionyr
Stock and Other Ownership Interests - Pionyr